TheraRadar
← Back
Data updated: Jun 28, 2026

MUNDIPHARMA

Pharma
RespiratoryOncologyImmunology Execution: Good

MUNDIPHARMA is a pharmaceutical company focused on Respiratory, Oncology, Immunology. Key products include REZZAYO.

2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2023)
1 Novel 1 Orphan 1 Priority Review 1 Fast Track
See 1 novel approval →
2023 REZZAYO (REZAFUNGIN ACETATE) Orphan · Priority Review · Fast Track

MUNDIPHARMA at a Glance

  • Fast trial execution (13 months median completion)

MUNDIPHARMA's Key Drugs

MUNDIPHARMA's core commercial portfolio centers on REZZAYO, spanning Respiratory and Oncology — its most strategically important drugs approved in the last 15 years.

REZZAYO
Infectious Disease

Candidemia

Approved 2023

MUNDIPHARMA's Recent FDA Approvals

New NDA/BLA approvals for MUNDIPHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MUNDIPHARMA's Therapeutic Areas

MUNDIPHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 42%
0 drugs Phase 3: 6 Phase 2: 4 Phase 1: 4
Oncology 33%
0 drugs Phase 3: 4 Phase 1: 12
Immunology 12%
0 drugs Phase 3: 1 Phase 1: 6
Neurology 7%
0 drugs Phase 3: 1 Phase 2: 1
Infectious Disease 6%
0 drugs Phase 3: 1 Phase 1: 1

MUNDIPHARMA Pipeline Snapshot

MUNDIPHARMA has 41 active clinical programs from ClinicalTrials.gov — 13 Phase 3, 5 Phase 2 and 23 Phase 1.

13
Phase 3
5
Phase 2
23
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • REZZAYO leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 6/9 completed
  • • Speed: 13 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges